BiotechTube

AUY922 + BYL719

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Conditions

Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Trial Timeline

Dec 1, 2012 → Mar 1, 2014

NCT ID
NCT01613950

About AUY922 + BYL719

AUY922 + BYL719 is a phase 1 stage product being developed by Novartis for Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein. The current trial status is completed. This product is registered under clinical trial identifier NCT01613950. Target conditions include Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01613950Phase 1Completed

Competing Products

20 competing products in Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

See all competitors
ProductCompanyStageHype Score
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
32
E0671 + rabeprazole sodium + E0671 placeboEisaiApproved
85
ParietEisaiPre-clinical
23
Ramucirumab + Placebo + Oxaliplatin + Leucovorin + 5-FluorouracilEli LillyPhase 2
52
Ramucirumab + Capecitabine + Cisplatin + S-1 + OxaliplatinEli LillyPhase 1
33
Ramucirumab + PaclitaxelEli LillyPhase 2
52
epoetin alfaJohnson & JohnsonPhase 3
77
MK0782MerckPhase 2
52
Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for PembrolizumabMerckPhase 3
77
Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + CapecitabineMerckPhase 3
77
Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for PembrolizumabMerckPhase 3
77
ECC + FOLFIRIRochePhase 3
77
Capecitabine + OxaliplatinRochePhase 3
77
Atezolizumab + Capecitabine + Oxaliplatin + DocetaxelRochePhase 2
52
Atezolizumab + Tiragolumab + Oxaliplatin + CapecitabineRochePhase 2
52
Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, CapecitabineAmgenPhase 2
51
AMG 337AmgenPhase 1/2
40
AMG 337AmgenPhase 2
51
Cisplatin + S-1 + SunitinibPfizerPhase 1
32
axitinib + capecitabine + cisplatinPfizerPhase 1
32

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85